These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fesoterodine (toviaz) for overactive bladder. Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719 [No Abstract] [Full Text] [Related]
3. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482 [TBL] [Abstract][Full Text] [Related]
4. Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence. Kenton K; Lowenstein L; Brubaker L Neurourol Urodyn; 2010 Apr; 29(4):555-7. PubMed ID: 19771598 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Babu R Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401 [TBL] [Abstract][Full Text] [Related]
6. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. Malone-Lee JG; Al-Buheissi S BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469 [TBL] [Abstract][Full Text] [Related]
7. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. Schaefer W J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326 [No Abstract] [Full Text] [Related]
8. Toviaz approved for overactive bladder. Traynor K Am J Health Syst Pharm; 2008 Dec; 65(23):2184. PubMed ID: 19020177 [No Abstract] [Full Text] [Related]
9. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. Cartwright R; Srikrishna S; Cardozo L; Robinson D BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389 [TBL] [Abstract][Full Text] [Related]
10. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. Nitti VW; Rovner ES; Bavendam T BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062 [TBL] [Abstract][Full Text] [Related]
11. Changing treatments for overactive bladder. Waine E; Stott M Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960 [TBL] [Abstract][Full Text] [Related]
12. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Choo MS BJU Int; 2011 Feb; 107(4):603-11. PubMed ID: 20860648 [TBL] [Abstract][Full Text] [Related]
13. Fesoterodine for the treatment of overactive bladder. Belavic JM Nurse Pract; 2009 Aug; 34(8):14-5. PubMed ID: 19638887 [No Abstract] [Full Text] [Related]
14. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103 [TBL] [Abstract][Full Text] [Related]
15. [Overactive bladder. When it's pressing, immediate help is indicated]. Widhalm S MMW Fortschr Med; 2008 May; 150(20):44-5. PubMed ID: 18605642 [No Abstract] [Full Text] [Related]